Azacitidine Reactions 1680, p63 - 2 Dec 2017 Haematological toxicities: case report In a retrospective study, a 66-year-old man developed thrombocytopenia, leucopenia and neutropenia during treatment with azacitidine [time to reactions onsets and outcomes not stated]. The man had a history of rheumatoid arthritis, resection of right thigh and antiphospholipid antibody syndrome (diagnosed at the age of 65). He was diagnosed with myelodysplastic syndrome (MDS) with neutrophilic dermatosis (ND). Following its relapse, he started receiving treatment with a single course of azacitidine 75 mg/m /day, infusions for 7 days (1 cycle of 28 days). Because of noticeable improvement in ND, he was released on day 25 of disease (day 15 of hospitalisation). His concomitant prednisolone dose was decreased, but on day 24 the ND flared up again, thus the prednisolone dose was increased and second course of azacitidine was administered, which led to quick improvement in ND, and no more flare up was observed. The grade 3 haematological toxicities included thrombocytopenia and leucopenia after the first course, as well as neutropenia in the st nd 1 and 2 courses. He continued to receive azacitidine and the therapy was completed after 12 courses. Author comment: Regarding adverse events, the patient developed grade 3 blood toxicity as defined by the Common Terminology Criteria for Adverse Events v4.0 (CTCAE), and included thrombocytopenia and leukopenia after the first course, as well as neutropenia in the 1st and 2nd courses. Kudo D, et al. Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine. Rinsho Ketsueki 58: 607-612, No. 6, 2017. Available from: URL: [Japanese; summarised from a translation] - Japan 803286002 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial